“I know where I am, and I know where I’m going and I know I’m going to get there. I’m going to be excited and enthusiastic every day that God gives me on this earth. I am going to dream my dreams.”

– jim valvano

1 2013 Annual Report Our Mission

The V Foundation for Cancer Research is a charitable organization dedicated to saving lives by helping to find cures for cancer. The V Foundation strives to make a difference by generating extensive, passionate support for cancer research and by creating an urgent awareness among all Americans of the importance of ending the disease in all its forms. The dedicated work of our many partners, volunteers and supporters has led to many extraordinary, tangible victories in the war against cancer. Through advocacy, education, fundraising, and philanthropy, The V Foundation continues to seize every opportunity to change lives and ultimately defeat cancer.

CEO Message

The V Foundation has spent 21 years funding research that brings together the brightest minds working to end cancer. We are proud to present our annual report, providing a snapshot of last year’s accomplishments. During fiscal year 2013, we funded $14 million in new cancer research grants, and continue to fund previous multi- year grants. We are making important progress! This report is also a prelude to the future – a look at how to expedite this fight, to make it as effective as possible, to enlist each of you in this effort so that we can end cancer. Thank you for your help and support. No one can change the course of cancer alone. We dedicate this report to everyone working together toward this goal. Please help us continue until there is no longer a need.

Susan Braun Chief Executive Officer 2013 Annual Report 2 2 013 Grants

The V Foundation awards three types of grants. The V Scholar grant directly funds young investigators to help them establish their own independent laboratory research projects. The Translational grant facilitates the transition of projects from the laboratory to the patient’s beside quickly and efficiently. The Designated grants are inspired by particular areas of scientific interest and/or geographic reach. They are selected on the basis of scientific merit, as determined by our scientific advisors.

V Scholars

Bjoern Schwer, M.D., Ph.D. Luis Carvajal-Carmona, Ph.D. Boston Children’s Hospital University of California, Davis Boston, MA Sacramento, CA Martin D. Abeloff, M.D. V Scholar Identification of Novel Breast Cancer Genes in a Neural Genome Rearrangements and Alternative Hispanic Isolate end Joining Processes in Initiation and Maintenance of Medulloblstoma Robert Doebele, M.D., Ph.D. University of Colorado School of Medicine Maximilian Diehn, M.D., Ph.D. Department of Medicine, Division of Medical Stanford Cancer Institute Oncology Stanford, CA Aurora, CO Investigating the KEAP1-NRF2 Pathway in Lung NTRK1 Gene Fusions as a Novel Oncogene Class Stem Cells and Lung Cancer and Therapeutic Target in Lung Cancer Albert Wyrick V Scholar Award Funded in Memory of Calvin Bradham with Funded by The Michael and Carole Marks support from Crown Imports Family Michael J. Emanuele, Ph.D. Rafael Bejar, M.D., Ph.D. Lineberger Comprehensive Cancer Center UCSD Moores Cancer Center University of North Carolina at Chapel Hill La Jolla, CA Chapel Hill, NC Pathogenic Mechanisms of Splicing Factor Identification of Ubiquitin Signaling Networks as Mutations in Myelodysplastic Syndromes Novel Avenues for Therapeutic Intervention

Timothy F. Burns, M.D., Ph.D. Summer Gibbs, Ph.D. University of Pittsburgh Cancer Institute Oregon Health & Science University Pittsburgh, PA Portland, OR Targeting KRAS Mutant Lung Adenocarcinoma Screening of Small Molecule Fluorophores to Probe through Inhibition of TWIST 1 Pancreatic Cancer Margins in the Operating Room Supported by UNICO National in Memory of Sue Speciale

3 2013 Annual Report Peter Hammerman, M.D., Ph.D. Ryan A. Wilcox, M.D., Ph.D. Dana-Farber Cancer Institute University of Michigan Comprehensive Boston, MA Cancer Center Targeting Fibroblast Growth Factor Receptor Ann Arbor, MI Fusions in Lung and Head and Neck Cancer Role of the T-cell Transcription Factor GATA-3 in Cutaneous T-cell Lymphomas Mei Kong, Ph.D. Beckman Research Institute of the City of Hope Kris C. Wood, Ph.D. Duarte, CA Duke Cancer Institute Targeting Glutamine Metabolism and the Durham, NC B55a-p53 Survival Pathway for Lymphoma Systematic Identification of Combination Therapies Treatment Targeting the Breast Cancer Microenvironment 2013 V Foundation Wine Celebration Vounteer Christopher A. Maher, Ph.D. Grant in Honor of John and Anne Sachs Siteman Cancer Center Washington University Chunling Yi, Ph.D. St. Louis, MO Lombardi Comprehensive Cancer Center Understanding the Role of Polycomb Associated Georgetown University LncRNAs in Prostate Cancer Washington, DC 2013 Vintner Grant – Funded by The Wine Interrogating the Role of Hippo-Yap Growth Celebration Regulatory Pathway in Kidney Cancer In Honor of Fred and Mary Constant, Jeff and Valerie Gargiulo, Dick and Ann Grace, Fred and Sally Schweiger, and Lowell and Janet Herrero

Michael Kharas, Ph.D. Memorial Sloan-Kettering Cancer Center , NY Understanding the MSI2 RNA Binding Protein Network in Leukemia

George-Lucian Moldovan, Ph.D. Penn State Hershey Cancer Institute Hershey, PA Dysregulation of the PARI Genomic Stability Pathway in Leukemia

Zeshaan Rasheed, M.D., Ph.D. The Sidney Kimmel Comprehensive Cancer Center , MD Regulatory Effects of the Tumor Microenvironment on Stem Cell Plasticity in Pancreatic Ductal Adenocarcinoma

Jatin Roper, M.D. Tufts Medical Center Boston, MA The Role of IWS1 and FGFR2 Isoform IIIc in Akt Isoform-dependent Colorectal Carcinogenesis

2013 Annual Report 4 2 013 Grants

2013 Translational Grants

Nika Danial, Ph.D. John V. Heymach, M.D., Ph.D. Margaret Shipp, M.D. Varsha Gandhi, Ph.D. Jarrod Marto, Ph.D. Christine Stellrecht, Ph.D. Dana-Farber Cancer Institute Carlo Toniatti, M.D., Ph.D. Boston, MA Timothy Heffernan, Ph.D. Fueling DLBCL Proliferation and Survival: A Role The University of Texas MD Anderson Cancer for Fatty Acid Metabolism Center Houston, TX Ralph Deberardinis, M.D., Ph.D. Attacking the Specific Vulnerability of LKB1- Kemp Kernstein, M.D., Ph.D. Mutant NSCLC to Energy Depletion Using an ATP Children’s Medical Center Research Institute at Mimetic Universtiy of Texas Southwestern Dallas, TX Ite A.Laird-Offringa, Ph.D. Funded in Memory of Christopher T. Carroll Barbara Gitlitz, M.D. Translational Studies in Lung Cancer Martin W. Kast, Ph.D. Metabolism: Creating New Paradigms in Diagnosis Kimberly Siegmund, Ph.D. and Therapy Lina Wang, M.D. Michael Wong, M.D., Ph.D. Gianpietro Dotti, M.D. USC Norris Comprehensive Cancer Center Cliona Rooney, Ph.D. Los Angeles, CA Caridad Martinez, M.D. Development of Immunotherapy for Small Cell Dan L. Duncan Cancer Center at Baylor College Lung Cancer using Novel Modified Antigens of Medicine Houston, TX Daniela Matei, M.D. Prevention and Treatment of Viral Infections and Kenneth P. Nephew, Ph.D. Leukemic Relapse after Allogeneic Stem Cell Indiana University Melvin and Bren Simon Transplantation Cancer Center Indianapolis, IN Benjamin L. Ebert, M.D., Ph.D. An Epigenetic Strategy for Restoring Carboplatin Ann Mullally, M.D. Sensitivity in Ovarian Cancer William Kaelin, Jr., M.D. David Steensma, M.D. Toshi Tanuiguchi, M.D., Ph.D. Brigham and Women’s Hospital Elizabeth M. Swisher, M.D. Boston, MA Fred Hutchinson Cancer Center Identifying and Targeting Oncogenic Pathways in Seattle, WA TET2 and IDH Mutant Myeloid Malignancies Defining Genomic Scarring and Functional DNA Variants that Predict Response to PARP Inhibitors Tanja A. Gruber, M.D., Ph.D. in a Clinical Trial for Recurrent Ovarian Cancer James R. Downing, M.D. St. Jude Children’s Research Hospital Pengbo Zhou, Ph.D. Memphis, TN Leonard Salta, M.D. Funded by the 2013 Gala Yao-Tseng Chen, M.D., Ph.D. In Honor of Dick and Lorraine Vitale Weill Cornell Medical College Identification of Active Compounds in Infantile New York, NY Acute Lymphoblastic Leukemia Ubiquitin Ligase as a Novel Diagnostic Marker and Therapeutic Target for Colorectal Cancer Funded by The V Foundation Wine Celebration In Honor of Steve Bornstein

5 2013 Annual Report 2013 Designated Grants

Lizi Wu, Ph.D. Amit K. Verma, M.D. Shands Cancer Center David J. Prezant, M.D. University of Florida Mayris Webber, M.P.H., Dr. P.H. Gainesville, FL Charles B. Hall, Ph.D. Regulation of Oncogenic NOTCH Signaling in Albert Einstein College of Medicine of Yeshiva Childhood Leukemia Universi-ty Funded by 2012 Dick Vitale Gala Bronx, NY In Memory of Caleb Gacobbe Early Detection of Hematologic Malignancies in New York City Firefighters Exposed to World Trade Daniel S. Wechsler, M.D., Ph.D. Center Dust after the 9/11 Attacks Duke University Medical Center Funded by The V Foundation Wine Celebration Durham, NC and Jimmy V Celebrity Golf Classic Therapeutic Targeting of Calm-AF10 Nuclear Export in Pediatric Leukemia St. Helena Hospital Funded by The Apple Gold Group Napa, CA Clinical Research Program at St. Helena Stuart Goldberg, M.D. Hospital Martin-O’Neil Cancer Center Hackensack University Medical Center Funded by The V Foundation Wine Celebration The John Theurer Cancer Center Hackensack, NJ Calvin Lee, M.D. The Use of Dynamic Single Cell Network Profile All Children’s Hospital to Predict Outcome in Newly Diagnosed Acute St. Petersburg, FL Myelogenous Leukemia (AML) BMI1’s Role in the Regulation of Myogenic Funded by Marketing Research Consultants Differentiation in Rhabdomyosarcoma In Memory of Mary Ann Ingoglia Funded by 2013 Dick Vitale Gala

Victoria Belancio, Ph.D. John Cavanagh, Ph.D. Tulane University North Carolina State Jimmy V Cancer Tulane Cancer Center Therapeutics Program New Orleans, LA Raleigh, NC Line-1 Contributing to Lung Cancer in Vivo Funded by 2013 Jimmy V Celebrity Golf Classic Funded by The Cancer Fund In Honor of the JVCGC 20 Year Volunteers

Shari Pilon-Thomas, Ph.D. James M. Ford, M.D. William E. Janssen, M.D. Stanford University School of Medicine H. Lee Moffitt Cancer Center & Research Stanford, CA Institute Funded by The Gastric Cancer Foundation Tampa, FL Gastric Cancer Genomic Research Adoptive Cell Therapy for Neuroblastoma Funded by 2012 Dick Vitale Gala Daniel S. Wechsler, M.D., Ph.D. In memory of Dave Heard Catherine P. Lavau, DVM, Ph.D. Duke University Medical Center Queen of the Valley Medical Center Durham, NC Napa, CA A Novel Role for the CRM1 Nuclear Export Funded by The V Foundation Wine Celebration Receptor in Leukemogenesis: Clinical Laboratory and Pathology Services Mechanisms and Targeting Herman Family Advanced Diagnostic and Surgical Funded by The Apple Gold Group Services Pavilion

2013 Annual Report 6 Board of Directors

The V Foundation Board of Directors is entrusted with and accountable for the strategic leadership and governance of the organization. Comprised of prominent business leaders, award- winning athletes and coaches, distinguished physicians and world-renowned entertainers, the Board provides governance and insight into sustaining and continually improving the Foundation’s efforts in the fight against cancer.

Jim Allegro Rosa M. Gatti Emeritus Director Retired Senior Vice President, Communications The V Foundation for Cancer Research Counsel and Corporate Outreach ESPN, Inc. Julie Allegro General Partner Mark King Allegro Venture Partners President Adidas Group North America Robert C. Bast, Jr., M.D. Vice President for Translational Research Philip H. Knight The University of Texas Chairman of the Board MD Anderson Cancer Center Nike, Inc.

George Bodenheimer Michael W. Krzyzewski Executive Chairman Head Coach, Men’s Basketball ESPN, Inc. Duke University

Steven M. Bornstein Eric Lautenbach Former President and Chief Executive Officer Director of Sports Marketing NFL Network Nike, Inc. Board Chair The V Foundation for Cancer Research Carl C. Liebert III President Bill Cosby USAA Capital Corporation

George W. Dennis III Robert E. Lloyd Retired Senior Partner Chair Emeritus Teague Campbell Dennis & Gorham, LLP The V Foundation for Cancer Research

David B. Fay Joe Loughrey Retired Executive Director Retired President and Vice Chairman United States Golf Association Cummins, Inc.

Michael C. Mac Donald Chairman and Chief Executive Officer Medifast 7 2013 Annual Report Michael E. Marks Stuart Taylor Founding Partner Chief Executive Officer Riverwood Capital, LLC The Taylor Group Geoffrey S. Mason Nicholas P. Valvano Senior Production Specialist President Emeritus ESPN, Inc. The V Foundation for Cancer Research Joseph O. Moore, M.D. Robert Valvano Professor of Medicine Sports Commentator Duke Cancer Institute Lesley Visser Robert C. Nakasone Sports Commentator Retired Chief Executive Officer CBS and HBO Toys “R” Us, Inc. Dick Vitale Donna Orender Sports Commentator Chief Executive Officer ESPN, Inc. and ABC Sports Orender Unlimited, LLC R.C. “Bucky” Waters Lawrence F. Probst III Retired Vice Chancellor Chairman of the Board Duke University Medical Center Electronic Arts Robert P. Wayman Harry E. Rhoads, Jr. Retired Chief Financial Officer and Chief Executive Officer Executive Vice President Washington Speakers Bureau Hewlett-Packard Company Robin Roberts Co-Anchor Director of Player Development ABC’s Good Morning America North Carolina State University John P. Saunders David W. Williams Sports Commentator Retired Senior Vice President ESPN, Inc. and ABC Sports Whirlpool Corporation Constance Skidmore Norby Williamson Retired Board Member – Managing Partner Executive Vice President, PricewaterhouseCoopers LLP Programming & Acquisitions ESPN, Inc. John Skipper Co-Chair Larry Woodard Disney Media Networks President and Chief Executive Officer President Graham Stanley Advertising ESPN, Inc. Susan Braun Tony F. Smith, Ph.D. Ex Officio Managing Director Chief Executive Officer Leadership Research Institute The V Foundation for Cancer Research Pamela Valvano Strasser Chairwoman The V Foundation for Cancer Research 2013 Annual Report 8 Scientific Advisory Committee

The Scientific Advisory Committee is composed of leading physicians and research scientists from prominent universities and cancer centers. The all-volunteer Committee reviews and recommends top-rated research projects from the brightest innovators exploring the mysteries of cancer. Their guidance safeguards the scientific merit of grant proposals and ultimately provides funding to the leading pioneers in the field of cancer research.

Martin D. Abeloff, M.D. H. Shelton Earp III, M.D. (In Memoriam) UNC Lineberger Sidney Kimmel Comprehensive Cancer Center Comprehensive Cancer Center

Paul F. Engstrom, M.D. Robert C. Bast, Jr., M.D. Fox Chase Cancer Center The University of Texas MD Anderson Cancer Center Olivera J. Finn, Ph.D. University of Pittsburgh William T. Beck, Ph.D. School of Medicine University of Illinois at Chicago

Richard I. Fisher, M.D. Lisa Coussens, Ph. D. Fox Chase Cancer Center Oregon Health & Science University

Nancy Davidson, M.D. James M. Ford, M.D. University of Pittsburgh Stanford University Cancer Institute School of Medicine

9 2013 Annual Report Susan Hilsenbeck, Ph.D. Richard O’Reilly, M.D. Baylor College of Medicine Memorial Sloan-Kettering Cancer Center

Theodore S. Lawrence, M.D., Ph.D. David Piwinica-Worms, M.D., Ph.D. University of Michigan The University of Texas Comprehensive Cancer Center MD Anderson Cancer Center

A. Thomas Look, M.D. Helen Piwinica-Worms, Ph.D. Dana-Farber Cancer Institute The University of Texas MD Anderson Cancer Center

John D. Minna, M.D. University of Texas Jerome Ritz, M.D. Southwestern Medical Center Dana-Farber Cancer Institute

David E. Schuller, M.D. Joseph O. Moore, M.D. The Ohio State University Duke Cancer Institute Comprehensive Cancer Center

William G. Nelson, M.D., Ph.D. Sidney Kimmel Comprehensive Jonathan W. Simons, M.D. Cancer Center at Johns Hopkins Prostate Cancer Foundation

Margaret A. Tempero, M.D. Brian Patrick O’Neill, M.D. UCSF Comprehensive Cancer Center Mayo Clinic Cancer Center

2013 Annual Report 10 Statement of Financial Position

September 30, 2013

Assets

CURRENT 2013 ASSETS: Cash and cash equivalents $ 11,730,389 Accounts receivable, net 213,495 Promises to give, net 2,136,430 Prepaid expenses 151,737

TOTAL CURRENT ASSETS 14,232,051

Property and Equipment, Net 48,515

OTHER ASSETS: Investments 22,446,454 Promises to give, net 3,413,097 Intangible assets 50,000

TOTAL OTHER ASSETS 25,909,551

TOTAL ASSETS $40,190,117

11 2013 Annual Report Liabilities & Net Assets

CURRENT 2013 LIABILITIES: Accounts payable and accrued expenses $ 55,188 Accrued payroll and related liabilities 53,968 Deferred rent 40,350 Grants payable 12,223,413

TOTAL CURRENT LIABiLITIES 12,372,919

LONG-TERM LIABILITiES: Grants payable, net 9,840,300

Total liabilities 22,213,219

NET ASSETS: Unrestricted: Board designated 5,517,136 Undesignated (3,589,825) 1,927,311 Temporarily restricted 3,932,576 Permanently restricted 12,117,011

TOTAL NET ASSETS 17,976,898

TOTAL LiabILITIES AND NET ASSETS $40,190,117

2013 Annual Report 12 Statement of Activities and Changes in Net Assets

For the year ended September 30, 2013

SUPPORT AND REVENUE: UNRESTRICTED Contributions and gifts $ 10,608,057 Special events: Contributions 1,592,397 Event income 204,611 Less: costs of direct benefits to donors (674,660) Net revenues from special events 1,122,348 License income 3,332 Investment income, net of fees 117,605 Unrealized gain on investments 213,597 Realized gain on investments 130,773 12,195,712 Net assets released from restrictions 6,082,391

TOTAL SUPpORT AND REVENUE 18,278,103

EXPENSES: Program Services 15,138,098 Supporting Services: Management and general 719,490 Fundraising expenses 1,071,164 Total Supporting Services 1,790,654

TOTAL EXPENses 16,928,752

changes in net assets 1,349,351

transfer of net assets 3,785,000

Net Assets – Beginning of new year (3,207,040)

Net assets – End of year $1,927,311

13 2013 Annual Report TEMPORARILY PERMANENTLY 2013 RESTRICTED RESTRICTED TOTALS $ 5,085,610 $ 145,899 $ 15,839,566

– – 1,592,397 – – 204,611 – – (674,660) – – 1,122,348 – – 3,332 266,906 – 384,511 513,399 – 726,996 314,326 – 445,099 6,180,241 145,889 18,521,852 (6,082,391) – –

97,850 145,889 18,521,852

– – 15,138,098

– – 719,490 – – 1,071,164 – – 1,790,654

– – 16,928,752

97,850 145,899 1,593,100

– (3,785,000) –

3,834,726 15,756,112 16,383,798

$3,932,576 $12,117,011 $17,976,898

2013 Annual Report 14 Grant Distribution by State

1994-2013

WA NH VT ME OR MN ID WI NY MA MI CT IA PA NJ NE OH UT IL IN MD CA CO WV MO VA DC KY TN NC AZ NM SC AL GA

TX LA

FL

HI

15 2013 Annual Report Grant Distributions by Cancer Site

1994-2013 (in millions)

General Cancer/Other ($23.5)

Leukemia/Lymphoma ($22.1)

Breast ($10.9)

Pediatric ($14.1)

Lung ($11.6)

GI ($4.0)

Prostate ($4.6)

Melanoma ($6.3)

Pancreatic ($5.5)

Brain ($3.3)

Gyn./Cervical/Ovarian ($3.1)

Renal ($2.9)

Head and Neck ($1.4)

Myeloma ($0.5)

Colon ($1.2)

Ewings ($0.8)

539 Total grants $115,436,054

2013 Annual Report 16 Thank You

Thank You for Your Passion, Friendship and Commitment!

People from all walks of life support The V Foundation for Cancer Research.

Your donations are making an impact, advancing life-saving research and providing hope to cancer patients and their loved ones.

Thank you for caring and for all the good things you do to support our cause.

Together, we will win the fight against cancer.

17 2013 Annual Report HOPE Begins in the dark. The road is long. The hills are steep. Only your support drives us forward.

1 2013 Annual Report 2013 Annual Report 18